Macro partitioning

SGLT2 inhibitors (dapagliflozin, empagliflozin, ipragliflozin) significantly reduce body weight in older adults with type 2 diabetes primarily through substantial fat mass loss, while causing only a modest, likely non-clinically meaningful reduction in skeletal muscle mass.

If you are an older adult with Type 2 Diabetes, SGLT2 inhibitors (like Jardiance or Farxiga) are effective for weight loss. Expect significant fat loss. You may lose a small amount of muscle, but it is not the primary driver of weight loss and is likely not clinically concerning for most. Monitor your strength if you are already frail, but the metabolic benefits of fat loss generally outweigh the modest muscle loss.